With our mission, team, and our technology we are committed to driving innovation, improving patient outcomes, and shaping the future of cardiovascular medicine.Our platform technology for AAV vectors empowers us to engineer new vectors with unparalleled organ specificity. We harness this platform to build our cardiac gene therapy vector portfolio, achieving unprecedented safety profiles in its development. Our portfolio of safe and precisely targeted AAV vectors, specifically tailored for the heart, forms the foundation of our gene therapy pipeline. We employ validated molecular targets to directly tackle the underlying molecular root causes of heart failure and other cardiac diseases.